Background-Impairment of ventilatory efficiency in congestive heart failure (CHF) correlates well with symptomatology and contributes importantly to dyspnea. ). Patients were compared with 101 healthy control subjects. Cardiopulmonary exercise testing was performed, and ventilatory efficiency was defined as the slope of the linear relationship of V CO 2 and ventilation (VE). Results are presented in percent of age-and sex-adjusted mean values. Forty-four events (37 deaths and 7 instances of heart transplantation, cardiomyoplasty, or left ventricular assist device implantation) occurred. Among V O 2 max, NYHA class, LVEF, total lung capacity, and age, the most powerful predictor of event-free survival was the VE versus V CO 2 slope; patients with a slope Յ130% of age-and sex-adjusted normal values had a significantly better 1-year event-free survival (88.3%) than patients with a slope Ͼ130% (54.7%; PϽ0.001). Conclusions-The VE versus V CO 2 slope is an excellent prognostic parameter. It is easier to obtain than parameters of maximal exercise capacity and is of higher prognostic importance than V O 2 max.
V entilatory efficiency is defined by ventilation relative to CO 2 production. Its most important determinant is the matching of ventilation and perfusion. In most patients with congestive heart failure (CHF), as in normal control subjects, ventilatory efficiency improves with exercise. It correlates very well with exercise capacity respectively V O 2 max 1 and closely relates to symptomatology. 2, 3 Both NYHA class and V O 2 max have been proven to be good predictors of prognosis in CHF. Therapy with ACE inhibitors known to improve prognosis also betters ventilatory efficiency. 3 Ventilatory efficiency can be derived from a moderate effort well before exhaustion and is highly reproducible. 1 
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Therefore, we investigated the impact of ventilatory efficiency in CHF on outcome and compared it with other prognostic parameters like left ventricular ejection fraction (LVEF), NYHA class, and V O 2 max. To maximize the physiological information from cardiopulmonary exercise testing (CPX), we normalized V O 2 max and the slope of ventilation (VE) versus V CO 2 for age and sex using our own control population. 4, 5 
Methods

Patients
We monitored 142 consecutive patients (117 men, 25 women; mean age, 51.6Ϯ10 years; range, 21 to 73 years) with CHF after performing CPX between June 1993 and November 1996. Mean and median follow-up until death or end of follow-up was 16 months. The cause of CHF was coronary artery disease (nϭ70), dilated cardiomyopathy (nϭ66), valvular heart disease (nϭ4), graft failure (nϭ1), and hypertensive heart disease (nϭ1). Eleven patients were in NYHA class IV, 78 in class III, and 45 in class II; 8 patients did not complain of symptomatic limitation (class I).
Symptoms were attributed to heart and not lung disease in all patients, albeit the mild abnormality of pulmonary function tests in some patients was thought to be secondary to heart disease. Current smoking status and smoking history are presented in Table 1 .
Origin and severity of CHF were determined by echocardiography (nϭ130), chest radiograph (nϭ114), or cardiac catheterization (nϭ95). Inclusion criteria were a V O 2 max Ͻ25 mL O 2 ⅐ kg Ϫ1 ⅐ min
Ϫ1
and either cardiothoracic ratio Ͼ0.5, echocardiographic left ventricular end-diastolic diameter Ն57 mm, or LVEF determined by contrast ventriculography or echocardiography Յ45%. Mean LVEF was 27% (median, 26%). One hundred nineteen patients were in sinus rhythm, 19 had atrial fibrillation, and 4 had pacemaker rhythm. Current medication included ACE inhibitors (89%), diuretics (69%), nitrates (67%), digitalis (52%), anticoagulants (30%), and antiarrhythmics (6%). Ten percent were on calcium antagonists, mainly for rate control, and 31% were on aspirin for coronary disease.
Control Subjects
One hundred one healthy volunteers 16 to 75 years of age (mean, 37Ϯ14 years) underwent CPX testing to establish age-and sexcorrected normal values. Forty-five were female (weight, 60Ϯ8 kg; height, 165Ϯ6 cm), 56 were male (weight, 78Ϯ12 kg; height, 179Ϯ9 cm). Results have been published in part elsewhere. 4 Linear regression analysis for age versus oxygen consumption and VE versus V CO 2 slope revealed the following mean normal value formulas: VE versus V CO 2 slope: 0.13ϫageϩ19.9 for men and 0.12ϫageϩ24.4 for women; V O 2 at the gas exchange anaerobic threshold (V O 2 AT): Ϫ0.17ϫageϩ28.6 for men and Ϫ0.16ϫageϩ24.2 for women; V O 2 max: Ϫ0.36ϫageϩ51.5 for men and Ϫ0.34ϫageϩ44.6 for women.
For prognostic analysis, oxygen consumption and VE versus V CO 2 slope values are presented as percent predicted (PP) from the individual age-and sex-corrected mean normal values.
Exercise Testing
In all patients and control subjects, a symptom-limited CPX test was performed according to the modified Naughton protocol 6 with a Medical Graphics CPX/D system. Details of our test protocol have been published earlier. 4 Great effort was undertaken not to stop exercise prematurely. However, indications to stop the test were a higher degree of AV block or ventricular tachycardia Ͼ5 consecutive beats at a rate Ͼ120/min, new atrial fibrillation, ST-segment depression Ͼ3 mm, or systolic blood pressure Ͼ260 mm Hg, as well as a progressive decrease in blood pressure.
V O 2 max was defined as the peak V O 2 measured, always occurring well beyond the anaerobic threshold. V O 2 at V O 2 AT was detected by the V-slope method, 7, 8 supplemented by simultaneous observation of end-tidal gas concentrations (PETO 2 /CO 2 ).
Ventilatory efficiency on exercise was measured by plotting VE against V CO 2 . This plot revealed a linear relationship (rϭ0.98 to 0.99). The ventilatory efficiency on exercise is represented by its slope. The nonlinear part of this relationship after onset of acidotic drive to ventilation 8 was excluded.
Lung Function Tests
Routine lung function tests, including total lung capacity (TLC), forced expiratory volume in 1 second (FEV 1 ), inspiratory vital capacity (IVC), and diffusion capacity for carbon monoxide (DLCO), were expressed as percent predicted of normal PP. Oxygen saturation was continuously measured percutaneously by pulse oximetry on the ear lobe. Breathing reserve was calculated as 100Ϫ(100ϫVE max / resting FEV 1 ϫ41). 9
Follow-Up Data on Prognosis
Follow-up events included overall deaths, cardiac transplantation (HTX), implantation of a left ventricular assist device (LVAD), or cardiomyoplasty. Most patients had a follow-up of Ͼ1 year. Minimal follow-up was 6 months. One patient was lost to follow-up.
Statistical Analysis
Results are presented as meanϮSD. For comparison between groups, the Mann-Whitney U test was used; to compare prognostic parameters, linear and logistic regression analyses were performed. Correlations were determined according to Bravais-Pearson or Spearman. The follow-up data were analyzed by Kaplan-Meier life-table analysis and the log-rank test. To define the cutoffs giving the best discrimination in defining the likelihood of event-free survival, univariate log-rank tests (Mantel-Haenszel) 10 were used. A multiple Cox regression analysis was performed using LVEF, V O 2 max, VE versus V CO 2 slope, age, TLC, and NYHA class. 11 Classification trees (CART) were constructed with subgroups internally as homogeneous and externally as heterogeneous as possible, measured on the corresponding log-rank test. 12, 13 The successive splits of the tree correspond to the features with the greatest prognostic importance. For diagnostic testing sensitivity, accuracy and ORs were estimated.
Results
Exercise Testing
Eighty-nine patients terminated exercise because of dyspnea, 15 because of angina, 13 because of fatigue, 10 because of nonspecific symptoms like vertigo and anxiety, and 15 because of the above-defined criteria. All exercise tests in control subjects were limited by exhaustion.
V O 2 AT and V O 2 max were 10.7Ϯ3.2 and 15.2Ϯ4.7 mL O 2 ⅐ kg Ϫ1 ⅐ min Ϫ1 (median, 57 and 47 PP), respectively, in the patient group. The VE versus V CO 2 slope was 39.3Ϯ16.4 (median, 128 PP). There was no difference between the 2 major etiologic subgroups.
At termination of exercise, patients used 44Ϯ15% of maximal breathing capacity; healthy volunteers, 59Ϯ12%. In patients and in all NYHA subgroups, V O 2 max was reached earlier after V O 2 AT than in normal subjects (V O 2 AT/V O 2 max in patients, 71Ϯ11%; in normal subjects, 58Ϯ9%; PϽ0.001; see Table 2 ). Termination of exercise because of angina or by 
Oxygen Desaturation and Lung Function Testing
In 6 of 142 patients, a significant decrease in oxygen saturation (Ն4%) was found (mean, 96% to 87%). Five of these were in NYHA class III, and 1 was in class IV. One had a small atrial septum defect, and 1 had suspected pulmonary embolism with extremely elevated VE versus V CO 
Follow-Up of Vital Status
Thirty-seven deaths occurred during follow-up. An additional 7 patients survived HTX, cardiomyoplasty, or LVAD implantation. Eight deaths occurred at various time intervals after prior HTX, LVAD, or cardiomyoplasty. Median event-free survival was 38 months (overall survival, 39 months). Univariate Kaplan-Meier analysis of event-free survival revealed significant survival differences (log-rank test) with cutoff points for V O 2 AT at 10 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 or 30, 45, and 50 PP; V O 2 max at 10, 12, and 14 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 or 45 PP; and VE versus V CO 2 slope at 35 and 40 L/L CO 2 or 125 and 130 PP. Figure 1 shows the event-free survival for the total group, and Figure 2a and Figure 3 .
The sensitivity and specificity of a VE versus V CO 2 slope with a cutoff of 130 PP for survival were 70.3% and 63.5%; positive and negative predictive values were 40.6% and 85.7%, accuracy was 65.3%, the OR was 4.1, and the 95% CI was 1.9 to 9.0.
Discussion
Dyspnea and Ventilatory Efficiency
The most widely used scale to measure dyspnea in CHF is the NYHA classification, which, in contrast to the Borg scale and pulmonary function tests, has been shown to contribute prognostic information independently of left ventricular function. 14, 15 One of the most prominent features of dyspnea in CHF is hyperpnea, ie, an increase in ventilation relative to gas exchange. It is caused by early anaerobic metabolism, an increase in anatomical dead space by increased breathing rate and low tidal volumes caused by secondary restrictive physiology or respiratory muscle fatigue, 16 a decreased PaCO 2 set point resulting from acidosis, disturbances of diffusion, 17 activation of muscle ergoreceptors, 18 and respiratory muscle deoxygenation. 19 The most important cause of hyperpnea, however, is the increase in physiological dead space by alveolar hypoperfusion 20, 21 Therefore, we investigated the prognostic importance of ventilatory efficiency in patients with CHF and compared it with other currently used prognostic parameters like LVEF, 22, 23 NYHA class, 24, 25 and V O 2 max.
Population Under Study
Patients suffered mainly from coronary disease or dilated cardiomyopathy similar to recently reported patients. 26 All patients had an LVEF Յ45%; all NYHA I patients had an LVEF Ͻ35%.
There was no difference in smoking status in patients with reduced compared with normal ventilatory efficiency. Differences in pulmonary function tests were small and thought to be secondary to CHF. Lungs were somewhat smaller in patients with reduced ventilatory efficiency, as has been shown in normal subjects under exercise 27 and in persons susceptible to high-altitude pulmonary edema. 28 This might contribute to V /Q mismatch by making a small ventilationperfusion inequality more important. The slight decrease in TLC in our patients, however, is unlikely to contribute to a larger extent to the decrease in ventilatory efficiency. Fortysix percent of patients had reduced ventilatory efficiency (median, 128 PP).
Similar to Veterans Administration Heart Failure Trial (V-HeFT) findings, 29 mean V O 2 max was 15.2 mL ⅐ kg Ϫ1 ⅐ min
Ϫ1
, and cardiocirculatory limitation was confirmed by the high breathing reserve at the end of exercise, low rate of oxygen desaturation, and absence of pulmonary disease.
The lack of any important correlation to LVEF is not unexpected, 23, 30 and an LVEF Յ30% might not give very useful information regarding prognosis. 14, 31 More than 70% of our population had an LVEF Յ30%.
Follow-Up of Vital Status and CHF Events
Prognostic parameters in CHF 24 include symptoms, 25, 32, 33 hemodynamics, LVEF, cardiothoracic ratio, 29 neurohormones, 34, 35 electrolytes, 36 and V O 2 max. 31, 37, 38 We used V O 2 PP derived from our own large control population. Among LVEF, NYHA class, age, and TLC, the VE versus V CO 2 slope was the most powerful indicator of prognosis in a multivariate analysis.
VE/V CO 2 ratio and slope are known to correlate to V O 2 max. 39 Our results demonstrate that the VE versus V CO 2 slope contains prognostic information in addition to and beyond the measurement of V O 2 max: Patients with a VE versus V CO 2 slope Ͼ130 PP had a 1-year mortality Ͼ40%, and even if V O 2 max were preserved, 1-year mortality was Ͼ20%. Ventilatory efficiency is easier to obtain than V O 2 max and can be derived from a submaximal exercise test. The high 
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negative predictive value of a normal ventilatory efficiency (ie, slope Յ130 PP) is of special clinical relevance for patients with low V O 2 max or those who cannot exercise until exhaustion.
Underlying Physiology and Study Limitations
This study lacks an explanation of how ventilatory efficiency affects prognosis in CHF. Although normal ventilatory control in CHF 40 has been shown, an uncoupling of ventilation from CO 2 production 41 has also been reported and thought to be due to activation of muscle ergoreceptors. However, substantial changes in arterial CO 2 tension have not been found, 40, 42, 43 and the changes in physiological dead space suggested by increased ventilation 40, 42, 43 and near-normal PCO 2 would thus be secondary. An alternative explanation is that the increase in physiological dead space is directly caused by alveolar hypoperfusion 44 resulting from impaired endothelial vasodilatory capacity [45] [46] [47] or neuroendocrine activation. 35, 48 If this theory is correct, the "muscle hypothesis" would not easily fit in.
A major diffusion disturbance 17, 49 is an unlikely explanation for the derangement of ventilatory efficiency because CO 2 diffuses much more easily than oxygen and a decrease in oxygen saturation has not been found in Ͼ95% of our patients. It might become important in severe CHF with prominent congestion.
Another limitation of our study is that not all patients stopped exercise for dyspnea or fatigue. This might introduce a considerable error through ischemic pump dysfunction. However, the reluctance to include patients with angina would not have reliably excluded silent ischemia, nor would it be meaningful to disregard some contribution of ischemia in a setting of CHF, whose leading cause is ischemic heart disease. Furthermore, dyspnea might be the only symptom of angina. Thus, in any exercise testing of CHF patients, ischemia is likely to play some part. The VE versus V CO 2 relationship should, on the contrary, be of special value in this population, because it is measured well before the onset of angina or ischemia. Furthermore, the exclusion of patients who stopped exercise before the onset of dyspnea or fatigue led to a similar ratio of V O 2 max/V O 2 AT. This indicates that our patients did not stop because of angina; rather, ischemia concurred with the limitation by CHF at the end of exercise in some of them.
Despite these limitations, our results show that measurement of the VE versus VCO 2 relationship offers a unique way of estimating the prognosis of patients with CHF. During preparation of this article, similar results have been obtained by an independent group. 50 Given the possibility of therapeutic influences on ventilatory efficiency, 3 this might also provide a useful tool to guide therapy, especially in severe CHF.
